

## **H1 2023 revenue: up 9% to €112.62m**

- ❖ **Growth by all Divisions**, with the exception of FINTECH, which nonetheless benefited from an upturn in Q2.
- ❖ **Effects of the French Digital Healthcare investment programme (*Ségur du Numérique en Santé*)**
  - The Group is continuing to install solutions qualifying for the Ségur French Digital Healthcare investment programme: €2m at 30 June 2023.
  - Sales revenues from the recurring portion of the Ségur programme: €0.6m.

(€m)	H1 2022	H1 2023	Change 2023 / 2022
Q1	49.36	56.25	+14% (*)
Q2	54.21	56.37	+4%
<b>H1</b>	<b>103.57</b>	<b>112.62</b>	<b>9%</b>

(\*) *Strong growth in Q1 reflecting a favourable comparison base (restructuring of the electronic labelling activity).*

As a reminder, to streamline business operations, organisational changes were implemented in H1 involving business transfers between Divisions:

- After buying out the minority interests, MULTIMEDS (Ireland) and I-MEDS (Germany) were transferred to the PHARMAGEST Division (Compliance segment) and CAREMEDS (United Kingdom) joined the AXIGATE LINK Division (Nursing Home segment);
- The ICT company developing *MEDILINK*, a solution for health centres and regional health professional communities, has joined forces with the MEDICAL SOLUTIONS Division to expand PROKOV EDITIONS' range.

Plus recent acquisitions:

- ATOOPHARM joined the PHARMAGEST Division,
- SPEECH2SENSE and PRATILOG are now part of the MEDICAL SOLUTIONS Division.

Consolidated for the first time in Q2, revenue generated by these entities was not material at 30 June 2023.

## **H1 2023 business highlights**

- **The PHARMAGEST Division** reported sales of €83.7m, up 9% from H1 2022
  - While growth by the PHARMAGEST Division was more subdued in Q2, revenue remained strong at €83.7m at 30 June 2023, up from €76.7m in 2022.
  - The growth drivers remained unchanged, with strong momentum in the electronic labelling market and, in Italy, new pharmacy software solutions.
  - This Division accounted for 74% of Equasens Group's total revenue.
  
- **The AXIGATE LINK Division** recorded revenue of €14.9m, up 6% from H1 2022, driven in particular by the long-standing Nursing Homes and Home Hospital business.
  - This Division accounted for 13% of Equasens Group's total revenue.
  
- **The E-CONNECT Division** had revenue of €8.1m, up 10% from H1 2022.
  - Q2's excellent performance (+17% to €4.1m) confirmed the benefits of the new industrial strategy of diversifying production sourcing enabling the Division to respond more rapidly to market needs.
  - This Division accounted for 7% of Equasens Group's total revenue.
  
- **The MEDICAL SOLUTIONS Division** reported revenue of €4.9m, up 13% on H1 2022 largely in response to the success of the latest version of the MédiStory software.
  - This Division accounted for 4% of Equasens Group's total revenue.
  
- **The FINTECH Division** had revenue of €1.1m, down 3% from H1 2022.
  - The financing brokerage activity continues to be impacted by high interest rates. Despite this, the Division has adapted its strategy by targeting more promising growth markets contributing to a return to growth in Q2.
  - This Division accounted for 1% of Equasens Group's total revenue.

## **2023 outlook**

- Continuing growth in H2 2023, with the launch of new products (mobility, security, SaaS offerings, etc.) boosting sales across all business segments.
- Confirmation of the business upturn for the FINTECH Division.
- The ongoing integration of recent acquisitions expected to enhance the Group's technology offering and accelerate growth.
- Backed by the financial resources to pursue external growth opportunities, the Group will remain attentive to potential acquisitions.

## **Financial calendar**

- **Publication H1 2023 results:** 29 September 2023 (after the close of trading).
- **H1 2023 results information meeting:** 2 October 2023 (by videoconference).
- **Publication of Q3 2023 revenue:** 9 November 2023 (after the close of trading).

### **About Group Equasens**

*Founded more than 35 years ago, Equasens Group, which now has more than 1,200 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.*

*Equasens Group's specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.*

*And reflecting the spirit of its tagline "more technology for more humanity", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.*



#### **Listed on Euronext Paris™ - Compartment A**

*Indexes: MSCI GLOBAL SMALL CAP - GAIA Index 2020 - CAC® SMALL and CAC® All-Tradable*

*Included in the Euronext Tech Leaders segment and the European Rising Tech label*



*Eligible for the Deferred Settlement Service ("Service à Règlement Différé" - SRD) and equity savings accounts invested in small and mid-caps (PEA-PME).*

*ISIN: FR 0012882389 – Ticker Code: EQS*

**Get all the news about the Equasens Group [www.equasens.com](http://www.equasens.com) and on [LinkedIn](#)**

#### **CONTACTS**

##### **Analyst and Investor Relations:**

Chief Administrative and Financial Officer: Frédérique SCHMIDT  
Tel. +33 (0)3 83 15 90 67 - [frederique.schmidt@equasens.com](mailto:frederique.schmidt@equasens.com)

##### **Media Relations:**

FIN'EXTENSO - Isabelle APRILE  
Tel. +33 (0)6 17 38 61 78 - [i.aprile@finextenso.fr](mailto:i.aprile@finextenso.fr)